(NASDAQ: SLS) Sellas Life Sciences Group's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Sellas Life Sciences Group's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast SLS's revenue for 2026 to be $4,422,005,190, with the lowest SLS revenue forecast at $4,290,538,533, and the highest SLS revenue forecast at $4,597,092,120. On average, 2 Wall Street analysts forecast SLS's revenue for 2027 to be $10,829,338,645, with the lowest SLS revenue forecast at $10,507,639,131, and the highest SLS revenue forecast at $11,258,271,331.
In 2028, SLS is forecast to generate $24,891,828,091 in revenue, with the lowest revenue forecast at $24,152,706,796 and the highest revenue forecast at $25,879,342,608.